| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. | Chief Financial Officer | Stock Option (right to buy) | 285,000 | 24 Jan 2025 | Direct | ||
| Rein Therapeutics, Inc. | Director | Stock Option (right to buy) | 17,500 | 23 Jul 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RNTX | Rein Therapeutics, Inc. | 23 Jul 2025 | 1 | $0 | 4 | Director | 23 Jul 2025, 19:38 |
| FULC | Fulcrum Therapeutics, Inc. | 24 Jan 2025 | 1 | $0 | 4 | Chief Financial Officer | 28 Jan 2025, 16:15 |
| ALRN | Aileron Therapeutics, Inc. | 02 Dec 2024 | 1 | $0 | 4 | Director | 06 Dec 2024, 16:32 |
| ALRN | Aileron Therapeutics, Inc. | 20 Aug 2024 | 1 | $0 | 4 | Director | 22 Aug 2024, 16:05 |
| FULC | Fulcrum Therapeutics, Inc. | 26 Jan 2024 | 1 | $0 | 4 | Chief Financial Officer | 30 Jan 2024, 21:05 |
| FULC | Fulcrum Therapeutics, Inc. | 17 Jan 2024 | 1 | $0 | 4 | Chief Financial Officer | 19 Jan 2024, 16:15 |
| ALRN | AILERON THERAPEUTICS INC | 31 Oct 2023 | 1 | $0 | 4 | Director | 02 Nov 2023, 20:53 |
| ALRN | AILERON THERAPEUTICS INC | 31 Oct 2023 | 0 | $0 | 3 | Director | 02 Nov 2023, 20:51 |
| FULC | Fulcrum Therapeutics, Inc. | 07 Aug 2023 | 1 | $0 | 4 | Chief Financial Officer | 09 Aug 2023, 16:16 |
| FULC | Fulcrum Therapeutics, Inc. | 07 Aug 2023 | 0 | $0 | 3 | Chief Financial Officer | 09 Aug 2023, 16:11 |